MedPath

Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer

Early Phase 1
Completed
Conditions
Recurrent Head and Neck Carcinoma
Interventions
Radiation: Brachytherapy
Procedure: Conventional surgery
Registration Number
NCT02467738
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Brief Summary

This pilot clinical trial studies cesium Cs 131 brachytherapy in treating patients with head and neck cancer that has come back (recurrent) and can be removed by surgery. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Radioactive drugs, such as cesium Cs 131, may carry radiation directly to tumor cells and not harm normal cells. Permanently implanting cesium Cs 131 into the wound bed after surgery may help treat microscopic cancer cells that may be in the tissue after surgical removal of the tumor.

Detailed Description

PRIMARY OBJECTIVES:

I. Assess the impact of cesium 131 (cesium Cs 131) on recurrence rate, disease free survival and over all survival.

SECONDARY OBJECTIVES:

I. Assess complications associated with cesium 131 treatment in subjects with head and neck cancer.

OUTLINE:

Patients undergo brachytherapy using cesium Cs 131 during surgical resection.

After completion of study treatment, patients are followed up at 30 days and then every 3 months for 24 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  1. Diagnosis: Subjects with a diagnosis of recurrent head and neck cancer
  2. Based on clinical and radiographic evidence the tumor needs to be deemed resectable preoperatively
  3. Age: Subjects must be ≥ 18 years of age and ≤ 90 years old
  4. Informed Consent: All subjects must be able to comprehend and sign a written informed consent document
Exclusion Criteria
  1. Subjects who are pregnant or may become pregnant
  2. Unresectable tumor
  3. Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cesium-131 BrachytherapyConventional surgeryPatients undergo brachytherapy using Cesium-131 during surgical resection
Cesium-131 BrachytherapyBrachytherapyPatients undergo brachytherapy using Cesium-131 during surgical resection
Cesium-131 BrachytherapyCesium-131Patients undergo brachytherapy using Cesium-131 during surgical resection
Primary Outcome Measures
NameTimeMethod
Disease free survival (DFS)Up to 24 months

Will assess the impact of cesium Cs 131 on DFS by comparing the cohort to a matched historical control cohort. The distribution of DFS will be estimated using the Kaplan-Meier and a stratified log rank test will be used to test for differences between cohorts. Adjustment for other potential confounders will be performed using stratified Cox proportional hazards regression

Incidence of toxicityUp to 90 days

Evaluated using the Radiation Therapy Oncology Group Common Toxicity Criteria

Categories of risk include infection, wound breakdown, inability to heal, fistula formation, bleeding and need for further surgery.

Secondary Outcome Measures
NameTimeMethod
Recurrence rateUp to 24 months

Comparisons of 6-month and one-year recurrence rates will be performed using logistic regression

Overall survivalUp to 24 months

The distribution of overall survival will be estimated using the Kaplan-Meier and a stratified log rank test will be used to test for differences between cohorts. Adjustment for other potential confounders will be performed using stratified Cox proportional hazards regression.

Complication rateUp to 24 months

Estimated by cohort along with exact 95% confidence intervals

Adverse event rateUp to 30 days

Evaluated using the National Cancer Institute, Common Terminology Criteria for Adverse Events version 4.0

Estimated by cohort along with exact 95% confidence intervals

Trial Locations

Locations (1)

Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath